Objective: Quantitative ultrasound of bone (QUS) and trabecular bone score (TBS) are recognized tools to explore bone health beyond BMD. The aim of our research was to explore the association of TBS with QUS measurements at phalangeal site in a setting of postmenopausal women taking aromatase inhibitors (AIs). Methods: BMD at lumbar spine, femoral neck and TBS were evaluated by a DXA densitometer (Hologic Discovery). Amplitude Dependent Speed of Sound (AD-SoS), Bone Transmission Time (BTT) and Ultrasound Bone Profile Index (UBPI) were detected at phalangeal site by Bone Profiler (Igea). Results: In 102 postmenopausal women (60 AIs treated and 42 controls), at baseline examination, TBS was negatively associated with age (r=-0.39, p<0.001) and positively related with T-score values at lumbar spine and femoral neck. After 18 months, AD-SoS, UBPI and BTT values were significantly decreased in BC women receiving AIs (-3.7%, -6.45%, -8.5%, respectively, p<0.001 for all), but not in controls (-0.7%, -3.53%, -2.97%, respectively). Change of BMD at lumbar spine was significantly different between AIs treated women and controls (-2.94%vs. -0.69%, p=0.001) and the same result was observed as for BMD at femoral neck (-2.5% vs. -0.39%, p=0.01). Percent change of TBS was significantly greater in AIs treated women in comparison with controls (-2.2% vs. - 0.4%, respectively, p=0.02). In AIs treated women, but not in controls, CTX levels significantly increased after 18 months [0.47 (0.36 to 0.62) vs. 0.66 (0.43 to 0.77), p=0.0004] and the same trend was observed as for BSAP levels [14 (13.01 to 15.57) vs. 15 (13.75 to 16.75), p=0.003]. At a multiple regression analysis, change of TBS was independently predicted by change of AD-SoS, after correcting for BMD change at lumbar spine and femoral neck and for modification of CTX and BSAP levels (β=0.37, SE=2.44, p<0.001). Conclusions: TBS modification was independently predicted by phalangeal QUS measurement in AIs treated BC women. Phalangeal QUS may represent an alternative tool to evaluate bone quality also in this setting of patients.
TRABECULAR BONE SCORE IS PREDICTED BY PHALANGEAL QUANTITATIVE ULTRASOUND IN BREAST CANCER POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS
Catalano, A
Writing – Review & Editing
;Bellone, FWriting – Review & Editing
;Agostino, RMWriting – Review & Editing
;Morabito, NWriting – Review & Editing
;GAUDIO, AGOSTINO;Lasco, AWriting – Review & Editing
2019-01-01
Abstract
Objective: Quantitative ultrasound of bone (QUS) and trabecular bone score (TBS) are recognized tools to explore bone health beyond BMD. The aim of our research was to explore the association of TBS with QUS measurements at phalangeal site in a setting of postmenopausal women taking aromatase inhibitors (AIs). Methods: BMD at lumbar spine, femoral neck and TBS were evaluated by a DXA densitometer (Hologic Discovery). Amplitude Dependent Speed of Sound (AD-SoS), Bone Transmission Time (BTT) and Ultrasound Bone Profile Index (UBPI) were detected at phalangeal site by Bone Profiler (Igea). Results: In 102 postmenopausal women (60 AIs treated and 42 controls), at baseline examination, TBS was negatively associated with age (r=-0.39, p<0.001) and positively related with T-score values at lumbar spine and femoral neck. After 18 months, AD-SoS, UBPI and BTT values were significantly decreased in BC women receiving AIs (-3.7%, -6.45%, -8.5%, respectively, p<0.001 for all), but not in controls (-0.7%, -3.53%, -2.97%, respectively). Change of BMD at lumbar spine was significantly different between AIs treated women and controls (-2.94%vs. -0.69%, p=0.001) and the same result was observed as for BMD at femoral neck (-2.5% vs. -0.39%, p=0.01). Percent change of TBS was significantly greater in AIs treated women in comparison with controls (-2.2% vs. - 0.4%, respectively, p=0.02). In AIs treated women, but not in controls, CTX levels significantly increased after 18 months [0.47 (0.36 to 0.62) vs. 0.66 (0.43 to 0.77), p=0.0004] and the same trend was observed as for BSAP levels [14 (13.01 to 15.57) vs. 15 (13.75 to 16.75), p=0.003]. At a multiple regression analysis, change of TBS was independently predicted by change of AD-SoS, after correcting for BMD change at lumbar spine and femoral neck and for modification of CTX and BSAP levels (β=0.37, SE=2.44, p<0.001). Conclusions: TBS modification was independently predicted by phalangeal QUS measurement in AIs treated BC women. Phalangeal QUS may represent an alternative tool to evaluate bone quality also in this setting of patients.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.